Navigation Links
Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
Date:5/31/2008

Company Announces Winners of the 'It's Your Passion. Let It Out' Contest

ISTANBUL, Turkey, May 31 /PRNewswire/ -- Bayer HealthCare today announced the 20th anniversary of the company's Kogenate(R) line of products and more than two decades of hemophilia A research, collaboration and community building at the 2008 World Federation of Hemophilia (WFH) World Congress in Istanbul, Turkey. More than 8 billion international units of Kogenate(R) and Kogenate(R) FS/KOGENATE(R) Bayer have been infused to date.

Kogenate(R) clinical trials began in May 1988 in Bonn, Germany. This advent of recombinant factor VIII technology represented a leap forward in the delivery of safe, effective treatment for people with hemophilia A. Since then, Bayer's Kogenate(R) line of products has maintained a record of safety, with two decades of clinical use and no confirmed case of pathogen transmission.

"Besides celebrating an impressive 20 years of safe, effective treatment, we are celebrating the many lives that have been touched through the use of our Kogenate(R) line of products," said Michael E. Mathews, general manager, hemophilia, and vice president of marketing, specialty medicine, Bayer HealthCare. "We are passionate at Bayer about improving the lives of people living with hemophilia. We are the only company with a long-acting recombinant factor VIII protein in human clinical trials. We are also creating new and innovative delivery systems that decrease the discomfort of infusion and increase convenience."

To celebrate its 20-year milestone, Bayer launched the "It's Your Passion. Let It Out" contest. Applicants from around the world expressed -- in the medium of their choice -- what they are passionate about as members of the hemophilia community. Representatives of the WFH served as contest judges and chose three entries to receive the grand prize, an all-expense-paid trip for two to the 2008 WFH World Congress. The winners are:

-- Mindy Ritchie, USA, video

-- Ilian Cori, Bulgaria, photography

-- Diego Constantino Sossa Centurion, Argentina, essay

All contest submissions will be on display at the World Congress and will appear at events around the world in 2008.

Bayer is committed to developing innovative hemophilia A treatments and expanding scientific and clinical knowledge that improves patient care. Over the past two decades, Bayer has:

-- Invested hundreds of millions of dollars in hemophilia research,

clinical trials and post-marketing studies to ensure the safety and

efficacy of its Kogenate(R) products.

-- Supported local and international hemophilia patient groups such as the

WFH in their advocacy and patient care initiatives.

-- Supported innovative educational and training programs to improve the

diagnosis and care of people with bleeding disorders around the world.

-- Donated more than 30 million international units of product to

countries with limited access to hemophilia treatment, bringing hope

and saving lives.

About Kogenate(R) FS

Kogenate(R) FS (Antihemophilic Factor [Recombinant]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate(R) FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate(R) FS. Please see the full prescribing information for important risk and use information at http://www.kogenatefs.com.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately 400,000 people around the world have hemophilia A.

About Bayer HealthCare LLC

Bayer HealthCare LLC is an affiliate of Bayer HealthCare AG. Bayer HealthCare AG is one of the world's leading, innovative companies in the healthcare and medical products industry, and based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports filed with the Frankfurt Stock Exchange. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE Bayer HealthCare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
4. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
5. Thomson Healthcare Cancer Profiler Used in Study
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
10. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
11. Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):